029 Group SE

M&A Activity • May 18, 2001

News Details

Ad-hoc | 18 May 2001 07:43

Ad hoc-Service: Rhein Biotech N.V. english

Ad hoc announcement processed and transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Rhein Biotech increases shareholding in PC Gen to 100% Maastricht, 18th May 2001 – The Rhein Biotech Group, specialised in vaccines, therapeutics and expression technologies today announced an increase in their shareholding in PC Gen from 51 to 100%. PC Gen, based in Buenos Aires produces and markets immune modulators, therapeutic substances which activate the immune system and are used in the treatment of serious diseases, for example cancer and hepatitis. PC Gen currently markets interferon, interleukin and erythropoietin in South America. Rhein Biotech acquired 51% of PC Gen in 1999, expanding its vaccine portfolio with complementary new products. The acquisition will further strengthen Rhein Biotech’s position in the rapidly growing markets in South America. Further information about Rhein Biotech is available from the contacts below: Valerie Ward, Investor Relations Rhein Biotech N. V., Maastricht (NL) T:+31 (0)43/356 78 98 F:+31 (0)43/356 78 99 e: investor@rheinbiotech.com Stephanie Krone vom Hoff Kommunikation GmbH, Düsseldorf T:+49 (0)211/515 805 16 F:+49 (0)211/515 805 55 e: s. krone@vomhoff.de end of ad hoc announcement (c) DGAP 18.05.2001 ——————————————————————————– WKN: 919544; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Stuttgart, Hannover 180743 Mai 01